Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients


Naval Military Medical University (Second Military Medical University)

Status and phase

Phase 2
Phase 1


Multiple Myeloma


Biological: GC012F injection

Study type


Funder types




Details and patient eligibility


This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of GC012F in high-risk, transplant eligible patients with NDMM.

Full description

Twenty evaluable subjects are planned to be enrolled in this study. Apheresis will be carried out in subjects who meet eligible criteria, and total 2 cycles of induction therapy (three-drug combination regimen based on bortezomib with details determined by the investigator according to the patient's condition) will be selectively given to subjects before or after apheresis. Next, subjects will receive a single infusion of GC012F, and the efficacy assessments will be performed at 1 month, 3 months, and every 3 months within 2 years until the end of the trial (MRD testing is required for each efficacy assessment), 1.Efficacy assessments performed at the 1st and 3rd months after infusion: <PR: Protocol change or transplantation or follow-up decided by the investigator. ≥PR: MRD positive: Protocol change or transplantation or follow-up decided by the investigator. MRD negative: Wait for next follow-up. 2.Efficacy assessments performed at the 6th month after infusion and every 3 months thereafter: MRD positive: Protocol change or transplantation or follow-up decided by the investigator. MRD negative: Whether to carry out maintenance treatment using lenalidomide until the end of the trial will be determined by the investigator. After signing the informed consent form (ICF), subjects will be followed up for efficacy and safety until 2 years after GC012F infusion, or disease progression, or death, or withdrawal of consent, or any intolerable toxicity, whichever comes first. All AEs in subjects, especially infection related symptoms and signs, will be closely monitored during follow-up, and prophylactic treatment will be administered according to clinical practice when necessary. In case of disease progression within 2 years after GC012F infusion, treatment will be administered according to clinical practice, and the survival follow-up (only for the survival status) will be performed every 12 weeks±14 days (2 weeks) until 2 years after infusion, or death, or withdrawal of consent, whichever comes first. For subjects who have undergone transportation or any other clinical routine treatments after GC012F infusion, survival follow-up will be also performed as described above.


20 estimated patients




18 to 70 years old


No Healthy Volunteers

Inclusion criteria

Patients should meet all of the following criteria:

≥18 years of age at the time of signing informed consent-upper age limit 70;

High-risk defined as meet one or more of the following criteria at screen:

  • R-ISS stage II or III;
  • LDH > the upper limit of normal;
  • Meet one or more of cytogenetic high risk defined by: del 17p, t(4:14), t(14:16); Gain 1q21≥ 4 copies;
  • Patients with extramedullary disease;
  • IgD or IgE subtype;
  • Meet one or more high-risk definition of mSMART3.0;

Documented evidence of multiple myeloma at diagnosis as defined by IMWG guidelines CRAB (calcium elevation, renal insufficiency, anemia, and bone abnormalities)/SLiM criteria, monoclonal plasma cells in the bone marrow ≥10% or presence of a biopsy proven plasmacytomas, and measurable secretory disease according to IMWG criteria meet one or more of the following criteria at screening:

  • Serum M protein ≥ 1 g/dL;
  • Urine M protein ≥ 200 mg/24h;
  • Serum free light chain sFLC ≥ 10 mg/dL with abnormal serum immunoglobulin κ/λ free light chain ratio.
  • ECOG score was 0-2 at screen;
  • Estimated life expectancy ≥3 months;
  • Absolute neutrophil count (ANC) ≥ 1.5×10^9/L without use of growth factors;
  • Platelet count ≥ 75×10^9/L without transfusion support within 7 days before the screen;
  • Hemoglobin≥ 80 g/L;

Adequate functional reserve of organs:

  • ALT/AST ≤ 2.5× UNL (upper normal limit);
  • Creatinine clearance ≥ 40mL/min, or serum creatinine level ≤177μmol/L,may be calculated or measured according to local practice;
  • Serum total bilirubin ≤ 1.5× UNL, except in subjects with congenital bilirubinemia, such as Gilbert syndrome, then direct bilirubin ≤ 1.5× UNL;
  • The left ventricular ejection fraction (LVEF)≥50%, and no clinically significant ecg abnormalities were found;
  • Basic oxygen saturation in natural indoor air: SPO2>92%.
  • Adequate venous access for apheresis collection, and no other contraindications to apheresis;
  • Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 1 year after CART cell infusion, serum HCG should be negative in females with fertility both at screening andbaseline;
  • Subjects must sign a written informed consent.

Exclusion criteria

Patients should be excluded if they meet any one of the following criteria:

  • Patients with purely non-secretory MM;
  • Subject has had radiation therapy within 14 days of screening;
  • Subjects has plasma cell leukemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes);
  • Subjects has a diagnosis of primary amyloidosis, Waldenstroem's disease, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma;
  • Having other tumors (excluding non-melanoma skin cancer and cervical cancer in situ bladder cancer and breast cancer that have been disease-free for more than 5 years);
  • Overt clinical evidence of dementia or altered mental status; any history of central nervous system (CNS) disease or neurodegenerative disorder, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain damage, dementia, Parkinson's disease, psychosis;
  • History of hereditary diseases such as Fanconi anemia, Schrader syndrome, Costerman syndrome, or any other known bone marrow failure syndrome;
  • Clinically significant cardiac disease including: uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities, grade III-IV heart failure or myocardial infarction cardiac angioplasty or stenting unstable angina or other clinically significant cardiac conditions within one year prior to enrollment;
  • Presence of any indwelling catheter or drainage tube (e.g., percutaneous nephrostomy catheter indwelling catheter bile drainage tube or pleural/peritoneal/pericardial catheter) permits the use of a dedicated central venous catheter;
  • Subjects is exhibiting clinical signs of meningeal involvement of multiple myeloma;
  • A positive virological result for any of the following: HIV, HCV, HBsAg, TPPA;
  • Other severe viral or bacterial infections or uncontrolled systemic fungal infections are present;
  • Subjects with a history of severe hypersensitivity;
  • There is a history of an autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that has resulted in terminal organ damage or requires systemic immunosuppressive/disease modulating drugs in the past 2 years;
  • Presence of lung disease (such as pulmonary fibrosis);
  • Subjects has had major surgery within 2 weeks before screen or has not fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study;
  • Poor compliance due to factors such as physiological family, social geography, etc., and inability to comply with the research program and follow-up plan;
  • Pregnant or lactating women, or men who are planned to have babies during the period of participation in the study or within 1 year of receiving treatment;
  • Investigator assessment deemed to be ineligible.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

20 participants in 1 patient group

GC012F treatment
Experimental group
GC012F will be infused at a dose of1- 3 x 10^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
Biological: GC012F injection

Trial contacts and locations



Central trial contact

Juan Du, MD

Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems